PriceTargets.com logo

Harmony Biosciences - HRMY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.63
  • Forecasted Upside: 35.01%
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$30.09 As of 04/16/2024 02:27 PM ET
▲ +0.57 (1.93%)

This chart shows the closing price for HRMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harmony Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRMY

Analyst Price Target is $40.63
▲ +35.01% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Harmony Biosciences in the last 3 months. The average price target is $40.63, with a high forecast of $59.00 and a low forecast of $27.00. The average price target represents a 35.01% upside from the last price of $30.09.

This chart shows the closing price for HRMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Harmony Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/23/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
1/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/16/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$49.00Low
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00Low
3/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$49.00N/A
2/27/2024MizuhoLower TargetBuy ➝ Buy$42.00 ➝ $40.00Low
2/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$49.00Low
2/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
2/16/2024MizuhoBoost TargetBuy ➝ Buy$33.00 ➝ $42.00Low
1/9/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$25.00 ➝ $28.00Low
1/2/2024Bank of AmericaReiterated RatingNeutral ➝ Underperform$30.00Low
11/1/2023Raymond JamesBoost TargetOutperform ➝ Outperform$26.00 ➝ $27.00Low
11/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$72.00 ➝ $42.00Low
10/16/2023Raymond JamesLower TargetOutperform ➝ Outperform$58.00 ➝ $26.00Low
10/16/2023Needham & Company LLCLower TargetBuy ➝ Buy$66.00 ➝ $53.00Low
10/4/2023MizuhoReiterated RatingBuy ➝ Buy$54.00Low
9/25/2023The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
9/22/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
9/19/2023MizuhoReiterated RatingBuy ➝ Buy$54.00Low
9/7/2023Berenberg BankInitiated CoverageBuy$59.00Low
8/29/2023MizuhoReiterated RatingBuy ➝ Buy$54.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00Low
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
8/3/2023MizuhoLower TargetBuy ➝ Buy$60.00 ➝ $54.00Low
8/2/2023Raymond JamesLower TargetOutperform ➝ Outperform$62.00 ➝ $58.00Low
8/2/2023Cantor FitzgeraldLower Target$75.00 ➝ $71.00Low
8/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
5/3/2023Cantor FitzgeraldBoost Target$71.00 ➝ $75.00Low
4/20/2023Bank of AmericaInitiated CoverageNeutralLow
4/17/2023Needham & Company LLCReiterated RatingBuy$67.00Low
3/29/2023MizuhoReiterated RatingBuy$60.00Low
2/22/2023The Goldman Sachs GroupLower TargetNeutral$49.00 ➝ $43.00N/A
2/22/2023MizuhoLower TargetBuy$70.00 ➝ $60.00Low
2/21/2023Needham & Company LLCReiterated RatingBuy$70.00Low
1/4/2023Piper SandlerBoost TargetOverweight$62.00 ➝ $70.00Low
11/8/2022MizuhoBoost TargetBuy$60.00 ➝ $70.00Low
11/3/2022Raymond JamesBoost TargetOutperform$60.00 ➝ $62.00Low
11/2/2022Needham & Company LLCBoost TargetBuy$60.00 ➝ $65.00Low
10/21/2022The Goldman Sachs GroupLower TargetNeutral$58.00 ➝ $51.00Low
10/14/2022Janney Montgomery ScottUpgradeNeutral ➝ Buy$57.00 ➝ $61.00Low
10/14/2022Jefferies Financial GroupUpgradeHold ➝ Buy$57.00 ➝ $61.00Low
8/4/2022MizuhoLower TargetBuy$64.00 ➝ $60.00Low
8/3/2022Raymond JamesBoost TargetOutperform$58.00 ➝ $60.00Low
8/3/2022OppenheimerBoost TargetOutperform$62.00 ➝ $67.00Low
8/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$57.00Low
7/12/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$55.00N/A
7/6/2022MizuhoInitiated CoverageBuy$64.00N/A
6/29/2022OppenheimerBoost TargetOutperform$55.00 ➝ $62.00Low
4/14/2022Cantor FitzgeraldInitiated CoverageOverweight$63.00Low
11/30/2021OppenheimerInitiated CoverageOutperform$55.00High
11/3/2021Raymond JamesInitiated CoverageOutperform$58.00Medium
9/22/2021Needham & Company LLCInitiated CoverageBuy$57.00Medium
3/29/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00 ➝ $43.00High
9/14/2020Jefferies Financial GroupInitiated CoverageBuy$51.00High
9/14/2020Piper SandlerInitiated CoverageOverweight$61.00High
9/13/2020The Goldman Sachs GroupInitiated CoverageNeutral$43.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2023
  • 12 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
10/19/2023
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 12 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2024
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 14 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 12 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Harmony Biosciences logo
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $30.09
Low: $29.36
High: $30.66

50 Day Range

MA: $32.14
Low: $29.37
High: $35.06

52 Week Range

Now: $30.09
Low: $18.61
High: $39.26

Volume

143,237 shs

Average Volume

371,936 shs

Market Capitalization

$1.71 billion

P/E Ratio

14.19

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Harmony Biosciences?

The following Wall Street analysts have issued stock ratings on Harmony Biosciences in the last year: Bank of America Co., Berenberg Bank, Cantor Fitzgerald, Mizuho, Needham & Company LLC, Piper Sandler, Raymond James, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for HRMY.

What is the current price target for Harmony Biosciences?

8 Wall Street analysts have set twelve-month price targets for Harmony Biosciences in the last year. Their average twelve-month price target is $40.63, suggesting a possible upside of 35.0%. Berenberg Bank has the highest price target set, predicting HRMY will reach $59.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $27.00 for Harmony Biosciences in the next year.
View the latest price targets for HRMY.

What is the current consensus analyst rating for Harmony Biosciences?

Harmony Biosciences currently has 2 sell ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HRMY.

What other companies compete with Harmony Biosciences?

Other companies that are similar to Harmony Biosciences include Amneal Pharmaceuticals, Supernus Pharmaceuticals, Protagonist Therapeutics, NewAmsterdam Pharma and Geron. Learn More about companies similar to Harmony Biosciences.

How do I contact Harmony Biosciences' investor relations team?

Harmony Biosciences' physical mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 484-539-9800 and its investor relations email address is [email protected]. The official website for Harmony Biosciences is www.harmonybiosciences.com. Learn More about contacing Harmony Biosciences investor relations.